ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 891

A Single Amino Acid In The β1 Chain Of HLA-DR Explains The Majority Of The HLA Association With Giant Cell Arteriti

Javier Martin1, F. David Carmona2, Jose Ezequiel Martin3, Aurora Serrano1, Lara Bossini-Castillo4, Roser Solans5, Jose A. Miranda-Filloy6, Santos Castañeda7, Maria C. Cid8, Jose A. Hernandez9, Inmaculada C. Morado10, Javier Narvaez11, Ricardo Blanco12, Bernardo Sopeña13, M. Jesus García-Villanueva14, Jordi Monfort15, Norberto Ortego-Centeno16, Ainhoa Unzurrunzaga17, Begoña Marí-Alfonso18, Cesar Magro19, Ana Hidalgo-Conde20, Marta Conde-Jaldon21, María F. González-Escribano21, Paul de Bakker22, Bobby P.C. Koeleman23 and Miguel A. González-Gay24, 1Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, 3Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 4Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, 5Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, 6Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 7Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 8Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 9Hospital Clinic. University of Barcelona, IDIBAPS,, Barcelona, Spain, 10Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 11Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 12Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, 13Thrombosis and Vasculitis Unit-Internal Medicine, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain, 14Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, 15Reumatologia, Hospital del Mar, Barcelona, Spain, 16Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain, 17Internal Medicine, Hospital de Galdakano, Vizcaya, Spain, 18Internal Medicine, Corporació Sanitaria Parc Taulí, Instituto Universitario Parc Taulí, UAB, Sabadell, Spain, 19Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 20Internal Medicine, Hospital Universitario Virgen de la Victoria, Málaga, Spain, 21Immunology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 22Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 23Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 24Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: genetics, giant cell arteritis and human leukocyte antigens (HLA)

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Giant cell arteritis (GCA) is a polygenic inflammatory disease affecting medium- and large-sized blood vessels in people elder than 50-years old. Although it is clear that GCA has an important genetic component, very little is known about the genetic susceptibility to this vasculitis. In order to better understand the genetic association of the HLA region with this disease, we aimed to carried out for the first time a comprehensive fine-mapping of this genomic region to identify the causative variants and/or amino acids responsible for the GCA predisposition.

Methods: 556 biopsy-proven GCA patients and 1,951 controls from Spanish Caucasian ancestry were genotyped using the Illumina Infinium Immunochip genotyping platform.  Subsequently, we isolated the genotyping data from the extended major histocompatibility complex (xMHC) region, located in chromosome 6, and used a previously validated imputation method to analyze the variation within the xMHC region of single-nucleotide polymorphisms (SNPs), classical HLA alleles and variable amino acids. For the imputation, we used the Beagle software and a reference panel comprised of 5,225 individuals of European origin with genotyping data of about 8,961 common SNPs and insertion-deletion polymorphisms across the xMHC region, and four digits genotyping data of the HLA class I and II molecules. Control quality filters were performed with the Eigensoft and Plink software.

Results: The accuracy reached after comparing 4 digit types with the corresponding imputed data was >90% for HLA-DQA1, HLA-DRB1 and HLA-B. As expected, one of the highest association peaks was HLA-DRB1*0404 (P=1.97×10-11, OR=2.91, CI 95%=2.13-3.98), but HLA-DQA1*0301 was also firmly associated (P=4.81×10-09, OR=1.70, CI 95%=1.42-2.03). Consequently, different amino acid positions of both DRβ1 and DQα1 chains were strongly associated with disease predisposition (P<5x10-8). However, the presence of a histidine in the position 13 of the DRβ1 molecule defined almost all the association of the HLA region with GCA. Only the addition of an arginine amino acid at position 56 of the HLA-DQα1 chain improved marginally the model (likelihood-P=0.018). Both amino acids are located in the binding pocket of their corresponding molecule and, therefore, may interact with the antigen.

Conclusion: Our results show that one amino acid located at the binding pocket of the HLA-DRβ1 chain is responsible for almost all the HLA association with GCA.


Disclosure:

J. Martin,
None;

F. D. Carmona,
None;

J. E. Martin,
None;

A. Serrano,
None;

L. Bossini-Castillo,
None;

R. Solans,
None;

J. A. Miranda-Filloy,
None;

S. Castañeda,
None;

M. C. Cid,
None;

J. A. Hernandez,
None;

I. C. Morado,
None;

J. Narvaez,
None;

R. Blanco,
None;

B. Sopeña,
None;

M. J. García-Villanueva,
None;

J. Monfort,
None;

N. Ortego-Centeno,
None;

A. Unzurrunzaga,
None;

B. Marí-Alfonso,
None;

C. Magro,
None;

A. Hidalgo-Conde,
None;

M. Conde-Jaldon,
None;

M. F. González-Escribano,
None;

P. de Bakker,
None;

B. P. C. Koeleman,
None;

M. A. González-Gay,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-single-amino-acid-in-the-%ce%b21-chain-of-hla-dr-explains-the-majority-of-the-hla-association-with-giant-cell-arteriti/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology